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Abstract
The prion strain 301V, is a mouse passaged form of bovine spongiform
encephalopathy (BSE).  It has been used as a model of BSE for more than 20
years, in particular in the investigation of tissue distribution of infectivity, the
molecular phenotype and transmission properties of BSE, strain typing assays
and prion inactivation studies. Most 301V experiments have required murine
bioassay as a method for the quantitation of infectivity. To date this model strain
has not been studied with the protein misfolding cyclic amplification assay
(PMCA) which detects prion-associated PrP  protein. The detection of BSE
PrP  by PMCA can be more sensitive than mouse bioassay and is carried out
in a much shorter time frame of days as opposed to months/years. Here, we
describe the development of a new highly sensitive and specific PMCA assay
for murine 301V and assess the sensitivity of the assay in direct comparison
with murine bioassay of the same material. This  assay detected, in a fewin vitro
days,  301V at a brain dilution of at least 1x10 , compared to bioassay of the
same material in VM mice that could detect down to a 1x10  dilution and took
>180 days. The 301V PMCA may therefore offer a faster and more sensitive
alternative to live animal bioassay when studying the BSE agent in VM mice.
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Introduction
The transmissible spongiform encephalopathies (TSE or prion 
diseases) form a group of infectious and fatal neurodegenerative 
diseases affecting several species of mammals for which there is no 
available treatment or cure. The cause is thought to be a novel infec-
tious agent (the prion), itself a misfolded isomer (PrPSc) of a benign 
cell associated protein known PrP or PrPC. This group of diseases 
include scrapie in sheep and goats, Creutzfeldt Jakob disease (CJD) 
in humans and bovine spongiform encephalopathy (BSE) in cattle. 
The UK BSE epizootic of the mid-1980s to early 1990s was the 
result of recycling BSE through the cattle food chain via a high 
protein feed additive known as meat and bone meal. It is thought 
that over 460,000 BSE infected UK cattle entered the human food 
chain before a ban on feeding specified risk materials to cattle 
came into force1. As a consequence of this, a new human disease 
referred to as vCJD, the human form of BSE, began to present in 
a number of young adults from the mid-1990s. This demonstration 
of the zoonotic potential of prion diseases generated an acceler-
ated program of research into these diseases and much of this has 
required animal models. The murine passaged BSE strain known 
as 301V was first described by Bruce and colleagues2 during trans-
mission studies of cattle BSE to wild type mice. BSE 301V is 
the product of serial passage within the VM mouse line and this 
combination of 301V/VM has been well characterised and used in 
numerous studies, including those aimed at understanding the 
fundamental brain pathology during neuropathogenesis3. In addi-
tion, the 301V/VM model has also been important in experiments 
analysing the effectiveness of various decontamination measures 
for BSE infectivity. For example, Taylor et al.4 demonstrated the 
effectiveness of formic acid in inactivating both 301V and scrapie 
in the context of occupational exposure to histological samples. 
This BSE model has also been used to show the lack of sufficient 
inactivation of BSE prions during historical rendering processes 
which resulted in the BSE outbreak in UK cattle5. For develop-
ment of safe procedures in the context of human health, 301V has 
been used to model vCJD in the fractionation of plasma and the 
safe manufacture of blood products6, and additionally has been 
used to estimate BSE infectivity that is likely to remain after proc-
esses in the derivation of bone gelatine from bovine products7. A 
further study by McLeod et al.8 screened a number of different 
proteases for their ability to reduce the infectious titre of 301V as a 
novel method for the decontamination of sensitive surgical instru-
ments. More recently, the availability of transgenic mice express-
ing the bovine PRNP transgene have become available, and with 
this their high susceptibility to bovine BSE prions has comple-
mented the use of 301V in these types of experiments. A study 
published by Giles et al.9 directly compared the effectiveness of 
decontamination of both bovine BSE and 301V in transgenic and 
VM mice, respectively. 301V was more sensitive to both heat 
and chemical denaturation than cattle BSE, suggesting that the 
physical properties of the 301V BSE strain have diverged slightly 
from those of cattle BSE. Despite the more recent availability of 
these transgenic rodent strains the 301V/VM infection system 
remains a useful, well characterised model for BSE in TSE 
research and allows direct comparison with numerous previous 
studies.
In the last 15 years or so prion research has been revolutionised by 
the demonstration of in vitro assays that are thought to replicate 
the molecular events occurring in vivo during prion infection and 
the conversion of PrPC to the disease isomer PrPSc. First reported 
by Saborio and colleagues in 200110 the protein misfolding cyclic 
amplification (PMCA) assay is able to replicate prions in vitro 
within a source of PrPC (generally produced from a healthy brain 
homogenate) during cycles of PrPC to PrPSc seeded conversion fol-
lowed by sonication with high frequency sound waves that break 
up aggregates of PrPSc to form new seeds or sites of nucleation. 
The products of this sensitive in vitro assay retain the biochemical 
characteristics of the prion seed and are infectious11. The sensitivity 
of the PMCA assay was improved by including the dilution of the 
reaction into fresh PrPC substrate after an optimal period of ampli-
fication. This modification, known as serial PMCA (sPMCA)12 
has been widely adopted by the research community and has been 
applied to several rodent prion strains13, scrapie in sheep14,15, BSE 
in cattle16, and CWD of cervids17. sPMCA can achieve levels of 
sensitivity significantly beyond that of animal bioassay18 and these 
experiments take days or weeks to perform compared to the months 
to years of animal bioassay, and at a fraction of the cost. As such, 
amplification of prions by sPMCA can be used as a surrogate for 
measuring infectivity in vivo. To date, the 301V strain of BSE has 
not been used in sPMCA based studies. Here, we describe a high 
sensitivity 301V sPMCA that can, over a period of 5 days detect 
higher dilutions of infectivity than are attained by a 170–200 day 
bioassay within the VM mouse line.
Results and discussion
Dataset 1. Raw uncropped images of the Western blots shown 
in Figure 1
http://dx.doi.org/10.5256/f1000research.9735.d138638 
A pool of 301V mouse brain homogenate was used to assess the 
efficacy of a new sPMCA assay alongside conventional 301V/VM 
bioassay. For the in vitro assay we used a 5 day amplification 
method and a murine VM substrate. This 301V sPMCA assay 
demonstrated assay sensitivity to 1×10-9 dilution of brain homoge-
nate (Figure 1A). The batch-to-batch variability test of a further 
3 substrate preparations detected 301V to at least the same 
level(Figure 1B). The observed variations in sensitivity within these 
limiting dilution experiments (between 10-9 and 10-11) is likely a 
reflection of differences in individual substrate preparations that 
will be seen when making small volume preparations from limited 
numbers of brains.
The same 301V sample was also analysed in a VM mouse 
bioassay by limiting dilution and this bioassay detected infectiv-
ity in 1 out of 12 mice at the 10-8 dilution of 301V brain material 
(Table 1), equating to a 301V titre of the original brain pool of 
108.5 LD50/g (as determined by Karber methodology19).
The 301V sPMCA assay can therefore detect PrPSc at a level at 
least tenfold more sensitive than the VM mouse bioassay, in a 
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Figure 1. sPMCA amplification of 301V BSE. A. Reactions were seeded with 10 µls of 10-4 to 10-13 dilution of 301V brain (as indicated). 
Unspiked samples had 10 µl VM brain substrate only. Sc, scrapie positive brain sample was used as a blotting control. B. The assessment 
of reproducibility of the 301V sPMCA using three separate batches of VM substrate, each were seeded with 301V brain dilutions 10-7 to 10-11 
(as indicated). Unspiked PMCA samples were always negative (a total of 15 replicates are shown). Western blots were probed with the 
anti-PrP antibody SHa31, M, molecular mass markers at 41, 30 and 22 kDa.
Table 1. Titration of 301V infected mouse 
brain. *Number of clinical and pathology 
positive mice/total injected. Mouse numbers 
exclude intercurrent deaths i.e. animals dying 
earlier than the 1st clinical case (there was 
one intercurrent death of a mouse receiving 
10-7 brain dilution, and two receiving the 10-4 
dilution). Total number of challenged mice were 








10-4 4/4 142 10
10-5 5/6 149 14
10-6 10/12 170 12
10-7 4/11 191 18
10-8 1/12 184 -
10-9 0/12 - -
total assay time taking little over a week. Whilst we report sensi-
tivity of the assay at 5 days of amplification, it is very likely that 
much higher levels of sensitivity could be attained with additional 
rounds of amplification. The highest dilution of 301V infectivity 
that could be detected within the VM bioassay was a 1×10-8 dilu-
tion of brain at 184 days post inoculation, or 26 times longer than 
the sPMCA assay. Maintaining animals within bioassay, including 
their category 3 containment make these kind of titration experi-
ments very costly and time consuming to carry out. That, coupled 
with the ethical implications of use of animals means sPMCA 
could be the method of choice unless there is a good scientific 
reason for requiring to demonstrate infectivity (the ability to cause 
disease), or a requirement to monitor strain phenotype, as opposed 
to the surrogate marker of disease, PrPSc protein. A useful way of 
incorporating these two assays into future studies, could be to assess 
301V seeding activity within a wide range of samples to identify 
those that contain PrPSc. Bioassay could then be used on a lim-
ited number of sPMCA-positive samples to confirm the presence 
of BSE infectivity. Another example of the application of sPMCA 
that has been routinely used for the detection of prions in a rodent 
Page 3 of 5
F1000Research 2016, 5:2529 Last updated: 18 OCT 2016
prion model is with cervid CWD17. In this instance, CWD amplifi-
cation within cervid CNS tissue substrate is notoriously inefficient, 
and transgenic mice have been used as an animal bioassay model 
for infectivity studies and also to provide substrate to facilitate effi-
cient in vitro amplification by sPMCA.
In summary, we have developed a reliable in vitro method 
(sPMCA) for the detection of PrPSc resulting from infection with 
301V (mouse passaged BSE). The assay is at least as sensitive as 
mouse bioassay and can derive data on the presence of PrPSc in a 
fraction of the time. This will be useful in studies such as those 
looking at BSE decontamination where the screening of large 
numbers of samples is required.
Materials and methods
All use of animals, the collection of animal tissues and the use 
of such tissue was carried out in accordance with the Animal 
(Scientific Procedures) Act (ASPA) 1986, under licences from 
the UK Government Home Office (Project licence 60/2544). All 
animal experiments were subject to review and approval (01-124) 
by The Roslin Institute Ethical Review Committee and euthanasia 
methods were approved by the UK Home Office.
Bioassay
A serial dilution of pooled murine VM brains that were taken 
from 301V challenged animals was made as previously described20. 
A dilution series of this brain homogenate from 10-1 to 10-10 was 
made up in saline and used to inoculate groups of VM mice, bred 
in house at The Roslin Institute and of mixed sex, 6 weeks old 
(groups of 6 mice at 10-4 and 10-5, 12 mice from 10-6 to 10-10) with 
20 µl of each dilution intracerebrally, as previously described20. 
Animals were observed daily for signs of ill health and euthanised 
by cervical dislocation when clinical signs of neurological disease 
or any intercurrent illness were observed. After euthanasia, brain 
tissue was confirmed as 301V positive or negative by detection of 
brain tissue vacuolation by light microscopy after Haematoxylin 
and Eosin staining20. This analysis was carried out blinded to the 
identity of the tissue in each case.
sPMCA
VM brains from healthy animals were supplied frozen, before 
preparation of the 10 % (w/v) homogenate substrate. Preparation 
of 10 % brain homogenates as substrates for sPMCA has been 
previously described21. Here, we included the sPMCA addi-
tive digitonin22 (Sigma-Aldrich) which was added to reactions at 
50 µg/ml. sPMCA reactions were assembled in 200 µl thin wall 
PCR tubes, and comprised 90 µl brain homogenate substrate with 
digitonin, three 2.4 mm Teflon beads (Precision plastic ball co. Ltd) 
and 10 µl of 301V sample to be amplified (10-4 to 10-13 dilution of 
301V brain). Unspiked negative control samples were set up substi-
tuting the 301V seed with 10 µl VM brain substrate only. Reaction 
tubes were placed in a Misonix S3000 sonicating water bath set on 
a program of 10 seconds sonication every 30 mins, for 24 hours at 
a power setting of 190–200 W at 37°C. Every 24 hours, samples 
were diluted 1 in 10 into fresh VM brain substrate and sonicated 
for a further 24 hour round of repeated sonication and incubation 
retaining the same three Teflon beads throughout the 5 rounds of 
sPMCA. Amplifications were carried out for a total of 5 days. Dilu-
tions of 301V brain homogenate are recorded as the dilution of 
brain spike before addition to the amplification reaction, ie 10-1 is 
10 µl of a 10 % (w/v) preparation of brain, 10-2 is 10 µl of a 1 in 10 
dilution of the 10-1 preparation of brain etc. All sPMCA was carried 
out at 37°C in a Misonix S3000 microplate horn.
Western blotting
sPMCA reaction products (10 µl) were digested using a final 
concentration of 50 µg/ml proteinase K (Sigma-Aldrich), for 
90 minutes at 40°C. Samples were then boiled for 5 minutes in 1X 
LDS buffer (Invitrogen) and electrophoresed through a NuPAGE 
SDS-PAGE gel system (Invitrogen) using 12% (w/v) acryla-
mide gels. Molecular mass markers (prestained Seeblue plus2, 
Invitrogen LC5925) were run alongside samples. As a blotting 
control an aliquot of proteinase K digested (50 µg/ml proteinase 
K (Sigma-Aldrich), 60 minutes at 40°C) scrapie positive ovine 
brain (equivalent to 2 µl of a 10% w/v brain homogenate) was 
also loaded onto each SDS-PAGE gel. Proteins were transferred 
to PVDF (Roche) membrane by electroblotting, and the mem-
branes were then blocked for 1 hour with 3 % (w/v) skimmed milk. 
Western blots were probed with the anti-PrP mouse monoclonal 
antibody SHa31 (SpiBio A03213) diluted to 1/80,000 and a poly-
clonal goat anti-mouse immunoglobulins Horse Radish Peroxi-
dase conjugate (Dako P04477), diluted to 1:20,000, as previously 
described21. Blots were imaged after the addition of EZ-ECL HRP 
substrate (Geneflow) using an ICCD225 photon counting camera 
system and IFS32 image software (Photek Ltd).
Data availability
F1000Research: Dataset 1. Raw uncropped images of the Western 
blots shown in Figure 1. 10.5256/f1000research.9735.d13863823
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